NEW YORK, Nov. 11 (GenomeWeb News) - Third Wave Technologies expects revenues from clinical molecular diagnostic products to expand to between $23 million and $26 million in 2005, the company said today.
The company said the revenue will be "driven chiefly by the company's core genetics, cystic fibrosis and HCV genotyping reagents."
Already have a GenomeWeb or 360Dx account?Login Now.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.